Research programme - monomethyl fumarate conjugates - V ClinBio

Drug Profile

Research programme - monomethyl fumarate conjugates - V ClinBio

Alternative Names: VCB 101; VCB 102; VCB 103; VCB 104; VCB 105; VCB 106

Latest Information Update: 27 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator V ClinBio
  • Class Antipsoriatics; Drug conjugates
  • Mechanism of Action NF E2 related factor 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Multiple sclerosis; Psoriasis

Most Recent Events

  • 27 Feb 2018 V Clinbio has patent protection for its drug product candidates in USA (V Clinbio pipeline, February 2018)
  • 27 Feb 2018 V Clinbio plans to file an IND application for VCB 101 for Multiple sclerosis in the second quarter of 2018
  • 27 Feb 2018 V Clinbio plans to file an IND application for VCB 102 for Psoriasis in the fourth quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top